Bukwang Pharmaceutical Co., Ltd.
KKRX:0030003,800.00
KRW
-65.00
(-1.68%)
ISIN
KR7003000007
Return %
Stock
S&P 500
1Y
6.15
14.39
3Y
-25.70
81.42
5Y
-69.34
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Je-Young Lee
- Full Time Employees
- 650
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 7, Sangdo-ro Seoul SL South Korea 06955
- IPO Date
- Aug 5, 1988
- Website
- bukwang.co.kr
- Similar Companies
- Business
- Bukwang Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company engaged primarily in the research, development, manufacturing, and marketing of innovative pharmaceutical products. Founded in 1960 and headquartered in Seoul, South Korea, Bukwang specializes in small molecule drugs across several therapeutic areas including central nervous system (CNS) disorders, metabolic diseases, oncology, immunology, and antiviral treatments. Its product portfolio includes prescription drugs such as LATUDA (lurasidone) for schizophrenia and bipolar depression; Levovir for chronic hepatitis B; Dexid for diabetic polyneuropathy; novel formulations for Parkinson’s disease dyskinesia (JM-010); and drugs targeting prostate cancer and immune disorders. The company also offers over-the-counter (OTC) products, health functional foods, and personal care items. In recent years, Bukwang has expanded its strategic focus on open innovation, combining its internal R&D capabilities with external partnerships and acquisitions. Notably, in 2021 it acquired Contera Pharma, a Danish biopharmaceutical company, to enhance its neurology pipeline, especially for the treatment of levodopa-induced dyskinesia in Parkinson’s disease with the asset JM-010. Further strategic development includes a significant investment partnership with OCI Company Ltd., a Korean energy and chemical enterprise, which acquired an 11% stake in Bukwang in 2022. This partnership aims to leverage OCI’s financial strength and Bukwang’s pharmaceutical expertise to accelerate R&D and expand its drug pipeline. Bukwang is also diversifying into advanced materials and environmental sectors such as semiconductors and secondary batteries, marking a significant operational expansion beyond pharmaceuticals. The company maintains extensive global connections through direct and indirect investments in more than 30 companies primarily in the U.S. and Europe. Bukwang continues to actively invest in R&D, focusing on innovative treatments ranging from CNS disorders, metabolic diseases, oncology to antiviral diseases, targeting global healthcare markets. It holds a distinguished position in Korea as one of the first companies with GMP certification and is recognized as an innovative pharmaceutical company for its R&D achievements and drug commercialization capabilities. Bukwang aims to sustain long-term growth by integrating new technologies and expanding its product pipeline through collaborations, joint ventures, and mergers and acquisitions.